The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.
The present invention relates to solid forms of the GPR119 agonist of Formula I and processes for their preparation thereof. In particular, the present invention relates to crystalline forms of the compound of Formula I and their preparation.
The present disclosure relates to oral pharmaceutical formulations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof (Formula I) wherein R, A and n are as described herein. The present disclosure also relates to processes for their preparation and their use in treating disorders such as cardiovascular and metabolic disorders, including diabetes.
The present disclosure relates to improved processes for the preparation and purification of a compound of Formula (I) and pharmaceutically acceptable salts thereof, and its intermediates.
The present disclosure relates to oral pharmaceutical formulations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof
The present disclosure relates to oral pharmaceutical formulations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof
The present disclosure relates to oral pharmaceutical formulations comprising a compound of Formula I or a pharmaceutically acceptable salt thereof
wherein R, A and n are as described herein. The present disclosure also relates to processes for their preparation and their use in treating disorders such as cardiovascular and metabolic disorders, including diabetes.
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
The present invention relates to solid forms of the GPR119 agonist of Formula I and processes for their preparation thereof. In particular, the present invention relates to crystalline forms of the compound of Formula I and their preparation.
The present invention relates to solid forms of the GPR119 agonist of Formula I and processes for their preparation thereof. In particular, the present invention relates to crystalline forms of the compound of Formula I and their preparation.
The present disclosure relates to improved processes for the preparation and purification of a compound of Formula (I) and pharmaceutically acceptable salts thereof, and its intermediates.
The present disclosure relates to improved processes for the preparation and purification of a compound of Formula (I) and pharmaceutically acceptable salts thereof, and its intermediates.
Euphorbia ProstrataEuphorbia ProstrataEuphorbia ProstrataEuphorbia ProstrataEuphorbia Prostrata after total dissolution study of about 30 minutes. The present invention further provides process for the preparation of above said compositions which are useful for the treatment of anorectal disease and colonic diseases such as hemorrhoids, fissures, cracks, fistulas, abscesses, and inflammatory bowel disease.
The present invention relates to a stable ophthalmic composition comprising loteprednol or its pharmaceutically acceptable salt thereof, one or more suspending agents, and optionally one or more excipients.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/567 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
The present invention relates to a stable pharmaceutical composition of therapeutically active agent, wherein the amount of nitrosamine impurity is below the FDA acceptable intake limit for shelf life of the pharmaceutical composition and a process for preparing the same.
The present invention relates to a pharmaceutical composition comprising Varenicline or its pharmaceutically acceptable salt with reduced amount of nitrosamine impurity and a process for preparing the same.
The invention relates to an extended release pharmaceutical composition comprising dydrogesterone or pharmaceutically acceptable salts thereof, one or more extended release polymer, optionally one or more pharmaceutically acceptable excipients.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/565 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
14.
PHARMACEUTICAL COMBINATION OF PPAR AGONIST(S) AND STEROL ABSORPTION INHIBITOR(S) AND USE THEREOF
The present invention relates to pharmaceutical combinations of peroxisome proliferator-activated receptor (PPAR) agonist(s) with sterol absorption inhibitor(s), as well as to the use of these combinations for treating and/or preventing non-alcoholic fatty liver disease (NAFLD) and/or non-alcoholic steatohepatitis (NASH) and other related disorders.
The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 (“ASK1”), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
C07D 491/107 - Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
16.
Fixed dose pharmaceutical composition of valsartan and sacubitril
This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases.
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
17.
COMBINATION THERAPY OF GPR119 AGONISTS AND DPP-4 INHIBITORS
The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto.
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/40 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/522 - Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/4162 - 1,2-Diazoles condensed with heterocyclic ring systems
A61K 31/403 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.
The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
The present invention relates to an ophthalmic composition comprising brinzolamide or pharmaceutically acceptable salts thereof, and brimonidine or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and their use for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
A61K 31/542 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
There is provided a dosages form comprising rivaroxaban and one or more pharmaceutically acceptable excipients. The present invention also provides a stable capsule dosage form comprising rivaroxaban and one or more pharmaceutically acceptable excipients. The invention also relates to process of preparation of such compositions.
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61J 3/07 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of capsules or similar small containers for oral use
The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
The present invention relates to combinations of GPR119 receptor agonists with DPP-4 inhibitors and their use thereof for treating or preventing cardiovascular and metabolic disorders, including diabetes mellitus, non-alcoholic fatty liver disease (NAFLD), NAFL, NASH, dyslipidemia, and related disorders thereto.
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to process for the preparation of a pyrrolidine compounds useful as key intermediate for the preparation of upadacitinib. More specifically the present invention relates to a process for preparing compound of Formula I, or pharmaceutically acceptable salts, polymorphs, isomers thereof. The present invention further provides a process for the preparation of upadacitinib using compounds of Formula I. Moreover, the present invention provides various crystalline solvates and crystalline hydrates of Upadacitinib or its pharmaceutically acceptable salts thereof.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
The present invention relates to inhibitors of apoptosis signal-regulating kinase 1 ("ASK1"), a process for synthesis of the compounds of the present invention, composition comprising the compounds and use of the compounds for inhibition of ASK1.
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
An object of the invention is to provide compounds as selective JAK1 inhibitor, a process for preparation of the inhibitors, a composition containing the compounds and utility of the compounds.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
13 4455 6786 7 88 is selected from straight or branched chain alkyl group. The present invention further provides a process for the preparation of elagolix or pharmaceutical acceptable salt by using compounds of Formula A.
The present invention relates to a novel process for the preparation of lifitegrast of Formula I. The present invention further provides a novel process for the purification of lifitegrast of Formula I.
The present invention relates to an ophthalmic composition comprising bimatoprost or pharmaceutically acceptable salts thereof and one or more pharmaceutically acceptable excipients. It further relates to a method of preparing such compositions and their use for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases.
A61K 9/24 - Layered or laminated unitary dosage forms
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/41 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
33.
SOLID FORMS OF ELAFIBRANOR AND PROCESS OF PREPARATION THEREOF
The present invention relates to solid forms of elafibranor of Formula I, and process of preparation thereof, wherein said solid forms includes amorphous, crystalline, solid dispersion and premix with pharmaceutically acceptable polymer and/or carrier.
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07C 323/52 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
C07C 323/22 - Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and doubly-bound oxygen atoms bound to the same carbon skeleton
C07C 67/30 - Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
34.
NOVEL COMPOUNDS AND THEIR USE IN PREPARATION OF ELAFIBRANOR AND PHARMACEUTICAL ACCEPTABLE SALTS THEREOF
EE)-2-(2,6-dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-en-1-yl)phenoxy)-2-methylpropanoic acid (Elafibranor) of Formula II and its pharmaceutical acceptable salts.
C07C 23/22 - Polycyclic halogenated hydrocarbons with condensed rings none of which is aromatic with a bicyclo ring system containing four carbon atoms
C07C 51/367 - Preparation of carboxylic acids or their salts, halides, or anhydrides by reactions not involving formation of carboxyl groups by introduction of functional groups containing oxygen only in singly bound form
C07C 47/56 - Compounds having —CHO groups bound to carbon atoms of six-membered aromatic rings containing hydroxy groups
C07C 59/74 - Unsaturated compounds containing —CHO groups
C07C 69/712 - Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
The present invention relates to a stable pharmaceutical composition comprising vasopressin or pharmaceutically acceptable salts thereof. The present invention further provides a method of increasing blood pressure in adults with vasodilatory shock by administering said pharmaceutical composition of vasopressin or pharmaceutically acceptable salts thereof.
The present invention provides a stable pharmaceutical composition comprising lifitegrast and one or more pharmaceutical excipients, wherein the pharmaceutical composition is free of antioxidant and/or preservative. It further relates to a method of preparing such compositions, filling into suitable single-dose or multiple-dose container and their use thereof in the treatment dry eye disease.
22Me, halogen or a leaving group. The present invention further relates to a process of preparation of pharmaceutical acceptable salts of fevipiprant and composition thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present invention relates to a novel process for the preparation of lifitegrast of Formula (I). The present invention further provides a novel process for the purification of lifitegrast of Formula (I).
A61K 31/00 - Medicinal preparations containing organic active ingredients
C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 407/06 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 217/26 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
41.
EXTENDED RELEASE PHARMACEUTICAL COMPOSITION OF APREMILAST
The invention relates to an extended release oral pharmaceutical composition comprising a core, wherein the core comprises apremilast or pharmaceutically acceptable salts, ester, solvates, polymorphs thereof, at least one extended release polymer and one or more pharmaceutically acceptable excipients, wherein the core is optionally coated with a film coating composition. The composition of the invention can be used for the treatment of psoriasis, psoriatic arthritis.
This present invention relates to pharmaceutical composition comprising fixed dose combination of valsartan or pharmaceutically acceptable salts thereof and sacubitril or pharmaceutically acceptable salts thereof. Further this invention also relates to process for the preparation of said composition and use of the said composition in treatment of certain diseases.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and medicinal preparations; sanitary
preparations for medical purposes, disinfectants, deodorants
and detergents for medical purposes; included in class 5.
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
A61K 31/4535 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
The present invention relates to novel compounds of formula (I) as GPR119 agonist, composition compositions containing such compounds and method of preparation thereof.
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
35 - Advertising and business services
Goods & Services
Medicinal, pharmaceutical and veterinary preparations. Surgical, medical, diagnostic, dental and veterinary
apparatus and instruments; orthopedic articles; suture
materials; artificial breasts, breast pumps, baby bottles,
baby pacifiers, blood testing apparatus, childbirth
mattresses, non-chemical contraceptives, condoms, droppers
and dropper bottles for medical purpose, dummies for babies,
feeding bottles, incubators for babies, medicine spoons,
electrical heating (medical) pads and abdominal pads. Advertising, distribution of advertising materials,
procurement services, import, export, marketing, wholesale
and retail services relating to pharmaceutical, medicinal
and veterinary preparations; wholesale and retail services
relating to surgical, medical, diagnostic and dental
apparatus and instruments.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical preparations for the treatment of respiratory system diseases; Pharmaceutical preparations for the treatment of gastrointestinal diseases; Pharmaceutical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Pharmaceutical preparations for the treatment of heart and cardiovascular diseases; Pharmaceutical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; Pharmaceutical preparations for the treatment of the musculo-skeletal system, namely connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; Pharmaceutical preparations for the treatment of infectious diseases, namely, urinary tract infections; Pharmaceutical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; Pharmaceutical preparations for the treatment of genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Pharmaceutical preparations for the treatment of reproductive system disorders, namely, sexual dysfunctions; Medical preparations for the treatment of respiratory system diseases; Medical preparations for the treatment of gastrointestinal diseases; Medical preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Medical preparations for the treatment of heart and cardiovascular diseases; Medical preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; Medical preparations for the treatment of the musculo-skeletal system, namely connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; Medical preparations for the treatment of infectious diseases, namely, urinary tract infections; Medical preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; Medical preparations for the treatment of genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Medical preparations for the treatment of reproductive system disorders, namely, sexual dysfunctions; Veterinary preparations for the treatment of respiratory system diseases; Veterinary preparations for the treatment of gastrointestinal diseases; Veterinary preparations for the treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; Veterinary preparations for the treatment of heart and cardiovascular diseases; Veterinary preparations for the treatment of neurological disorders, namely, brain injury, spinal cord injury, seizure disorders; Veterinary preparations for the treatment of the musculo-skeletal system, namely connective tissue diseases, bone diseases, spinal diseases, back pain, fractures, sprains, cartilage injuries; Veterinary preparations for the treatment of infectious diseases, namely, urinary tract infections; Veterinary preparations for use in dermatology, namely, dermatitis, skin pigmentation diseases, sexually transmitted diseases; Veterinary preparations for the treatment of genitourinary diseases, namely urological diseases, infertility, sexually transmitted diseases, inflammatory pelvic diseases; Veterinary preparations for the treatment of reproductive system disorders, namely, sexual dysfunctions;
(1) Business management; Business administration; Office functions, namely, telephone voice message transcription services, appointment scheduling services, appointment reminder services, and office machines and equipment rental; Television advertisement for others; Magazine advertisement for others; Radio advertisement for others; Newspaper advertisement for others.
45 - Legal and security services; personal services for individuals.
Goods & Services
(1) Business management; Business administration; Office functions, namely, telephone voice message transcription services, and office machines and equipment rental; Preparing and placing television advertisement for others; Preparing and placing magazine advertisement for others; Preparing and placing radio advertisement for others; Preparing and placing newspaper advertisement for others
(2) Office functions, namely, appointment scheduling services and appointment reminder services.
The present invention relates to novel fluoroquinolone carboxylic acid compounds and derivatives of Formula-I, and their salts wherein, R represents H or halogen. The present invention also relates to the use of novel fluoroquinolone carboxylic acid compounds and derivatives of Formula-I for preparation of Besifloxacin hydrochloride.
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
72.
Process for the preparation of moxifloxacin hydrochloride
4)bis(acyloxy-O)borate with (S,S)-2,8-diazabicyclo[4.3.0]nonane to give 1-cyclopropyl-7-[S,S]-2,8-diazabicyclo-[4.3.0]non-8-yl)-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinoline carboxylic acid hydrochloride (Moxifloxacin hydrochloride) of Formula-I with high purity.
